Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONITUX rituximab pharmacokinetics in ANCA-associated vasculitis
2015-001807-29Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rituximab in granulomatosis with polyangiitis (GPA) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by CHU Saint-Etienne. Primary endpoint: Clinical non-response at 6 months. Started Jul 2015; status: completed.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2015-001807-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001807-29.